AlphaCentric Advisors LLC Purchases New Position in Tempus AI, Inc. $TEM

AlphaCentric Advisors LLC purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 10,000 shares of the company’s stock, valued at approximately $452,000.

Other institutional investors also recently bought and sold shares of the company. Aberdeen Group plc lifted its stake in Tempus AI by 64.2% in the 4th quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock valued at $15,530,000 after buying an additional 102,878 shares in the last quarter. Pictet Asset Management Holding SA increased its stake in Tempus AI by 291.3% during the 4th quarter. Pictet Asset Management Holding SA now owns 48,488 shares of the company’s stock worth $2,948,000 after buying an additional 36,096 shares in the last quarter. Bogart Wealth LLC raised its holdings in shares of Tempus AI by 365,087.5% during the fourth quarter. Bogart Wealth LLC now owns 58,430 shares of the company’s stock valued at $3,450,000 after acquiring an additional 58,414 shares during the last quarter. Alethea Capital Management LLC acquired a new position in shares of Tempus AI during the fourth quarter valued at approximately $1,863,000. Finally, Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Tempus AI by 1.2% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after acquiring an additional 41,728 shares in the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TEM has been the subject of several recent research reports. Wolfe Research assumed coverage on Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tempus AI in a research note on Wednesday, June 17th. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. BTIG Research restated a “buy” rating and set a $80.00 price target on shares of Tempus AI in a research report on Monday, June 1st. Finally, Freedom Capital raised shares of Tempus AI to a “hold” rating in a research note on Tuesday, June 30th. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Tempus AI has an average rating of “Hold” and a consensus target price of $68.92.

Tempus AI Stock Performance

NASDAQ TEM opened at $52.47 on Monday. The stock has a fifty day simple moving average of $51.60 and a 200-day simple moving average of $54.00. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. The stock has a market cap of $9.42 billion, a PE ratio of -30.51 and a beta of 3.46. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32.

Tempus AI (NASDAQ:TEM) last announced its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The company had revenue of $348.12 million during the quarter, compared to analyst estimates of $345.44 million. During the same quarter last year, the firm posted ($0.24) earnings per share. Tempus AI’s revenue was up 36.1% compared to the same quarter last year. Equities analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Insider Activity at Tempus AI

In related news, CEO Ryan Fukushima sold 33,284 shares of Tempus AI stock in a transaction that occurred on Wednesday, July 8th. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76. Following the completion of the sale, the chief executive officer owned 167,763 shares in the company, valued at approximately $9,627,918.57. This trade represents a 16.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 8,703 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $383,541.21. Following the completion of the sale, the executive vice president directly owned 128,215 shares in the company, valued at approximately $5,650,435.05. The trade was a 6.36% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 616,043 shares of company stock worth $31,748,593. Company insiders own 24.26% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.